Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
MDGL Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
36.10%
MDGL Stock Analysis
MDGL
PE Ratio:
MDGL
PEG Ratio:
Not Available
MDGL
Forward EPS Growth (12 month):
0.00%
MDGL
PS Ratio:
9.9
MDGL
PSG Ratio:
0.2
MDGL
Forward Revenue Growth (12 month):
49.60%
MDGL Articles
No data was found